Physician profile
Frank A Bucci
NPI 1366425704
$245,820.17
in general payments reported to CMS, 2019-2025
29 companies · $63K in 2025
The $63K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $73K · 2021: $4,707 · 2022: $10K · 2023: $3,825 · 2024: $63K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $122K · Food and Beverage: $7,314 · Honoraria: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $122,137.50 |
| Food and Beverage | $7,314.27 |
| Honoraria | $625.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $120,672.81 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Ocular Therapeutix, INC. | $63,878.86 | 2019-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $39,354.55 | 2019-2025 | Tecnis Iol, Compact Intuitiv, Ifs Advanced Femtosec Laser |
| Tearlab Corp | $4,818.45 | 2022-2024 | Tearlab Osmolarity System, Scoutpro Osmolarity System |
| Lensar, INC. | $4,634.31 | 2019-2025 | Lensar Laser System |
| Allergan, INC. | $3,326.36 | 2019-2021 | |
| Glaukos Corporation | $2,456.11 | 2019-2025 | Idose, Istent Infinite, Idosetr |
| New World Medical,INC. | $1,514.81 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Carl Zeiss Meditec, INC. | $765.15 | 2019-2023 | |
| Alcon Vision LLC | $640.48 | 2019-2023 | Centurion |
| Tarsus Pharmaceuticals, INC. | $557.17 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $544.58 | 2020-2025 | Cequa, Bromsite, Xelpros |
| Bausch & Lomb Americas INC. | $318.15 | 2022-2025 | Envista Mx60 Iol, Envista Envy Iol, Envista Envy |
| Abbvie INC. | $297.95 | 2022-2024 | Durysta |
| Rayner Intraocular Lenses Limited | $294.44 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $264.11 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $222.79 | 2019 | |
| Shire North American Group INC | $220.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $134.91 | 2019-2023 | |
| Ivantis, INC | $128.97 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $120.98 | 2019 | |
| Staar Surgical Company | $119.96 | 2019 | |
| Beaver-Visitec International, INC. | $118.74 | 2025 | |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Biotissue Holdings INC. | $90.07 | 2021-2025 | |
| Sight Sciences, INC. | $83.64 | 2024 | Omni Surgical System |
| Omeros Corporation | $61.57 | 2019-2021 | |
| Harrow Eye, LLC | $58.06 | 2024-2025 | Iheezo |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$142,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Bucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.